Fractyl Health Inc GUTS
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if GUTS is a good fit for your portfolio.
News
-
Fractyl Health Reports First Quarter 2024 Financial Results and Provides Business Updates
-
Fractyl Health Presents Clinical Update on Revita® German Real-World Registry for Patients With Advanced Type 2 Diabetes (T2D)
-
Fractyl Health to Present at BofA Securities 2024 Health Care Conference
-
Fractyl Health to Report First Quarter 2024 Financial Results and Provide Business Updates on May 13, 2024
-
Fractyl Health Announces Multiple Presentations at the Upcoming Digestive Disease Week (DDW) 2024 Conference and the German Diabetes Association (DDG) Annual Meeting
-
Fractyl Health Expands Leadership with Appointment of Adrian Kimber as Chief Commercial Officer to Spearhead Anticipated Launch Preparation as the Company Conducts Two Pivotal Studies for Revita in Obesity and Type 2 Diabetes
-
Fractyl Health Shares Drop After Wider 4Q Loss
-
Fractyl Health Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
Trading Information
- Previous Close Price
- $6.66
- Day Range
- $6.45–6.62
- 52-Week Range
- $5.81–14.50
- Bid/Ask
- $6.53 / $6.64
- Market Cap
- $313.25 Mil
- Volume/Avg
- 161,255 / 308,227
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 3,524.76
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Fractyl Health Inc is a metabolic therapeutics company focused on pioneering new approaches to the treatment of metabolic diseases, including type 2 diabetes and obesity. The company focuses on transforming metabolic disease treatment from chronic symptomatic management to durable disease modifying therapies that target the organ level root causes of T2D and obesity.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- —
- Total Number of Employees
- 84
- Website
- https://www.fractyl.com
Valuation
Metric
|
GUTS
|
---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 3.81 |
Price/Sales | 3,524.76 |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
Metric
|
GUTS
|
---|---|
Quick Ratio | 9.15 |
Current Ratio | 9.38 |
Interest Coverage | — |
Quick Ratio
GUTS
Profitability
Metric
|
GUTS
|
---|---|
Return on Assets (Normalized) | −75.78% |
Return on Equity (Normalized) | — |
Return on Invested Capital (Normalized) | — |
Return on Assets
GUTS
Biotechnology Industry Comparables
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Wmfrbfcf | Gcymz | $593.5 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Kjjwnyr | Rhybq | $113.7 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Jcyztsxx | Dysspm | $106.7 Bil | |
MRNA
| Moderna Inc | Qlvmhbb | Ryfdl | $50.8 Bil | |
BNTX
| BioNTech SE ADR | Srnhpmg | Ljx | $22.4 Bil | |
ARGX
| argenx SE ADR | Pktshkpf | Txd | $22.2 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Kxhzcbdzr | Xqfrxmx | $19.1 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Pjvbpfj | Bpxbm | $14.6 Bil | |
INCY
| Incyte Corp | Mxncyjxp | Gnmyyyh | $12.8 Bil | |
RPRX
| Royalty Pharma PLC Class A | Twqmcmlmh | Bdsvbw | $12.6 Bil |